US pharmaceutical company SynAgile has received approval to begin the SCOL (Study of Continuous Oral Levodopa) Phase 2 clinical trial in Luxembourg. SCOL is a unique international clinical trial aiming to assess the safety, tolerability and efficacy of the new DopaFuse System for the continuous oral delivery of levodopa to better treat the symptoms of Parkinson’s Disease (PD).

SCOL aims to evaluate whether the novel DopaFuse System can reduce the fluctuation of levodopa levels in the blood, compared to the standard intermittent oral delivery of levodopa tablets. The clinical trial will also assess whether the system is safe, well tolerated and effective in relieving motor symptoms.

The SCOL study is yet another instance of the pioneering clinical efforts carried out in Luxembourg.

The clinical trial, which is being conducted concomitantly in Italy, Spain and Luxembourg, has the potential to revolutionise the treatment of this common neurodegenerative disease by facilitating drug delivery and reducing side effects. Luxembourg has a longstanding expertise in Parkinson’s Disease exemplified by joint initiatives such as the National Centre of Excellence in Research on Parkinson’s Disease.

We are confident that our highly collaborative approach will allow us to generate meaningful results and contribute to improving clinical outcomes for our PD patients.

Professor Rejko Kruger will act as the Luxembourg Institute of Health’s Principal Investigator. Rejko Krueger, MD, is a Professor of Clinical and Experimental Neuroscience, head of the Department for Translational Medicine at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg and a movement disorders specialist at Centre Hospitalier de Luxembourg (CHL).

Read more: